Description: Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.
Home Page: www.roche.com
Konzern Hauptsitz
Basel,
4070
Switzerland
Phone:
41 61 688 11 11
Officers
| Name | Title |
|---|---|
| Dr. Severin Schwan Ph.D. | CEO & Exec. Director |
| Dr. Alan Hippe | Chief Financial & Information Officer |
| Ms. Cristina A. Wilbur | Chief People Officer |
| Dr. Johannes Carolus Clevers M.D., Ph.D. | Head of Roche Pharma Research & Early Devel. |
| Dr. Thomas Schinecker | Chief Exec. Officer of Roche Diagnostics |
| Mr. William N. Anderson | Chief Exec. Officer of Roche Pharmaceuticals |
| Dr. Bruno Eschli | Head of Investor Relations |
| Ms. Claudia Bockstiegel | Gen. Counsel |
| Ms. Pascale Schmidt | Chief Compliance Officer |
| Ms. Barbara Schadler | Head of Group Communications |
Exchange: SW
Country: CH : Switzerland
Currency: Swiss Franc (CHF)
| Forward PE: | 14.2045 |
|---|---|
| Trailing PE: | 16.4895 |
| Price-to-Book MRQ: | 9.6286 |
| Price-to-Sales TTM: | 3.7259 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 100920 |